Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00746369 · ClinicalTrials.gov registry record · NA
IMARA, Adapting SiHLE for Detained African American Adolescent Females
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 188
- Enrollment target
NCT00746369: Completed NA study, sponsored by Emory University.
NCT00746369 is a NA study that has completed, run by Emory University. The registered enrollment target is 188 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00746369, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 188 participants
- Enrollment target
Study Summary
The IMARA Program will test the efficacy of a multi-session HIV Prevention program, adapted from an existing program(SiHLE), for incarcerated African American adolescent females.
Interventions
- BEHAVIORAL IMARA HIV Prevention Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2008-10 |
| Est. Completion | 2012-08 |
| Phase | NA |
What the finished NCT00746369 record still lists
NCT00746369 is an interventional study that assigns participants to a tested intervention. The registered 188 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which IMARA HIV Prevention Intervention is the first listed.
NCT00746369 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00746369 about?
NCT00746369 is a clinical study titled "IMARA, Adapting SiHLE for Detained African American Adolescent Females". The IMARA Program will test the efficacy of a multi-session HIV Prevention program, adapted from an existing program(SiHLE), for incarcerated African American adolescent females.
What is the current status of trial NCT00746369?
This trial is currently completed. It is a NA study. The enrollment target is 188 participants. The study started on 2008-10. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00746369?
The interventions under investigation include: IMARA HIV Prevention Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT00746369?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00746369's enrollment target sits among peer trials
188 576th of 2000 higher than 1,422 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422198 · 188 participants · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
- NCT04469790 · 188 participants · NA
Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
- NCT04671667 · 188 participants · Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- NCT04853251 · 188 participants · Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia